(Q38920328)

7 September 2017

title

Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity (English)

1 reference

7 September 2017

0 references

Gerhard Hamilton

1

1 reference

7 September 2017

Barbara Rath

series ordinal

2

1 reference

7 September 2017

language of work or name

English

0 references

publication date

22 February 2017

1 reference

Expert Opinion on Biological Therapy

7 September 2017

published in

1 reference

7 September 2017

volume

17

1 reference

7 September 2017

issue

4

1 reference

7 September 2017

page(s)

515-523

1 reference

Malignant melanoma-The cradle of anti-neoplastic immunotherapy

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Cancer immunotherapy: the beginning of the end of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Advances in immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

21 January 2018

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Immunotherapy as a strategy for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

B7 family checkpoint regulators in immune regulation and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

The PD-1 pathway in tolerance and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Genomic Approaches to Understanding Response and Resistance to Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

The non-small-cell lung cancer drug market.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Oncology meets immunology: the cancer-immunity cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

The new B7s: playing a pivotal role in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Enlarging the repertoire of therapeutic monoclonal antibodies platforms: domesticating half molecule exchange to produce stable IgG4 and IgG1 bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

PD-L1 blockade for cancer treatment: MEDI4736.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Combination immune therapies to enhance anti-tumor responses by NK cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Macrophages are critical effectors of antibody therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Three major uncertainties in the antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Merkel Cell Carcinoma Therapeutic Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Reply to M.C. Chamberlain and T.J. Kruser.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

What does PD-L1 positive or negative mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

The effect of chemotherapy/radiotherapy on cancerous pattern recognition by NK cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14712598.2017.1294156

10.1080/14712598.2017.1294156

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference